80876-00-2

Usage

Chemical structure

benzophenone derivative with a bromine atom at the 3-position and an amino group at the 2-position of the benzene ring

Primary use

building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds

Biological activities

studied for potential biological activities

Reactant

used in the production of various organic substances

Hazards

should be handled with caution as it can pose hazards to human health and the environment if not properly managed

Upstream product

• 80876-00-2 (2α,3aβ,7aβ)-octahydro-1H-indole-2-carboxylic acid 1,1-dimethylethyl ester 
• 80875-98-5 (2S,3aS,7aS)-perhydroindole-2-carboxylic acid 
• 115-11-7 isobutene 
• 3770-50-1 2-carbethoxyindole 
• 80828-13-3 (+/-)-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 
• 79799-08-9 (2S,3aS,7aS)-Octahydro-indole-2-carboxylic acid ethyl ester 
• 82864-25-3 ethyl (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylate hydrochloride 
• 79854-42-5 Ethyl (S)-indoline-2-carboxylate hydrochloride 
• 79815-20-6 (S)-indoline-2-carboxylic acid 
• 107045-53-4 (2S,3aS,7aS)-1-(benzyloxycarbonyl)octahydro-1H-indole-2-carboxylic acid 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 615583-05-6 C₂₇H₄₀N₂O₅ 
• 80828-32-6 Indolapril hydrochloride 
• 108449-51-0 (2S,3aS,7aS)-1-[(S)-2-((R)-1-Carboxy-3-phenyl-propylamino)-propionyl]-octahydro-indole-2-carboxylic acid 
• 80828-34-8 Indolapril diacid 
• 108449-50-9 (2S,3aS,7aS)-1-[(S)-2-((R)-1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-indole-2-carboxylic acid 
• 80828-33-7 tert-butyl (2S,3aS,7aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydro-1H-indole-2-carboxylate 
• 80828-33-7 (2S,3aS,7aS)-1-[(S)-2-((R)-1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-indole-2-carboxylic acid tert-butyl ester 
• 80876-04-6 (2R,3aR,7aR)-1-[(S)-2-((S)-1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-indole-2-carboxylic acid tert-butyl ester 
• 80828-33-7 (2R,3aR,7aR)-1-[(S)-2-((R)-1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-indole-2-carboxylic acid tert-butyl ester 
• 80923-95-1 (2R,3aR,7aR)-1-[(S)-2-((S)-1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-indole-2-carboxylic acid 
• 80876-05-7 (2R,3aR,7aR)-1-[(S)-2-((S)-1-Carboxy-3-phenyl-propylamino)-propionyl]-octahydro-indole-2-carboxylic acid 
• 108449-53-2 (2R,3aR,7aR)-1-[(S)-2-((R)-1-Carboxy-3-phenyl-propylamino)-propionyl]-octahydro-indole-2-carboxylic acid 
• 108449-52-1 (2R,3aR,7aR)-1-[(S)-2-((R)-1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-indole-2-carboxylic acid; hydrochloride 
• 107133-36-8 perindopril erbumine 

Relevant academic research and scientific papers

Continuous Flow Synthesis of ACE Inhibitors From N-Substituted l-Alanine Derivatives

A strategy for the continuous flow synthesis of angiotensin converting enzyme (ACE) inhibitors is described. An optimization effort guided by in situ IR analysis resulted in a general amide coupling approach facilitated by N-carboxyanhydride (NCA) activation that was further characterized by reaction kinetics analysis in batch. The three-step continuous process was demonstrated by synthesizing 8 different ACE inhibitors in up to 88 % yield with throughputs in the range of ≈0.5 g h?1, all while avoiding both isolation of reactive intermediates and process intensive reaction conditions. The process was further developed by preparing enalapril, a World Health Organization (WHO) essential medicine, in an industrially relevant flow platform that scaled throughput to ≈1 g h?1.

Inhibitors of hepatitis C virus NS3·4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics

Reversible tetrapeptide-based compounds have been shown to effectively inhibit the hepatitis C virus NS3·4A protease. Inhibition of viral replicon RNA production in Huh-7 cells has also been demonstrated. We show herein that the inclusion of hydrogen bond donors on the P4 capping group of tetrapeptide-based inhibitors result in increased binding potency to the NS3·4A protease. The capping groups also impart significant effects on the pharmacokinetic profile of these inhibitors.